Biogen (NASDAQ:BIIB) Given New $214.00 Price Target at Stifel Nicolaus

Biogen (NASDAQ:BIIB) had its target price hoisted by equities research analysts at Stifel Nicolaus from $202.00 to $214.00 in a research note issued on Friday,MarketScreener reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 6.37% from the company’s current price.

BIIB has been the subject of a number of other reports. Mizuho boosted their price objective on Biogen from $177.00 to $207.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Wedbush boosted their price target on shares of Biogen from $143.00 to $178.00 and gave the stock a “neutral” rating in a report on Friday, January 23rd. Guggenheim increased their price objective on shares of Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Tudor Pickering set a $157.00 price objective on shares of Biogen in a research report on Monday, November 3rd. Finally, Wells Fargo & Company boosted their target price on shares of Biogen from $155.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Eleven analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $194.23.

Biogen Stock Up 8.5%

Biogen stock opened at $201.18 on Friday. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41. The stock’s fifty day simple moving average is $176.94 and its 200-day simple moving average is $156.67. The company has a current ratio of 2.72, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $29.51 billion, a P/E ratio of 18.34, a P/E/G ratio of 1.56 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the business posted $3.44 earnings per share. Biogen’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities analysts expect that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 748 shares of Biogen stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This trade represents a 10.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by company insiders.

Institutional Investors Weigh In On Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Biogen during the second quarter worth about $284,358,000. Orion Porfolio Solutions LLC grew its stake in Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after buying an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec increased its position in Biogen by 718.2% during the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after buying an additional 499,676 shares during the period. AQR Capital Management LLC lifted its stake in Biogen by 30.7% in the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after buying an additional 418,776 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Biogen by 190.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after acquiring an additional 409,591 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat on both EPS ($1.99 vs. consensus ~1.72) and revenue ($2.28B vs. ~$2.21B); investors reacted favorably to the upside. BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat ’26 EPS View
• Positive Sentiment: Biogen raised FY‑2026 adjusted EPS guidance to $15.25–$16.25, above consensus — a major driver of the rally as it signals stronger full‑year profitability expectations. Biogen forecasts annual profit above estimates as Leqembi sales pick up
• Positive Sentiment: Sales of Leqembi and newer launches (Skyclarys, Zurzuvae) showed meaningful growth and helped offset MS declines, supporting upside to future revenue mix and margins. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Positive Sentiment: Recent analyst support (RBC buy) and favorable coverage helped sentiment alongside the earnings/guidance beat. Biogen (BIIB) Receives a Buy from RBC Capital
• Neutral Sentiment: Management released the full earnings slide deck and call transcript — useful for modeling guidance assumptions and product-level trends but not market-moving on its own. Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Core MS franchise continued to decline, driving overall revenue down ~7.2% YoY; management said MS revenue pressures will persist, which limits near‑term top‑line growth. Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
• Negative Sentiment: Some outlets note Biogen “swung to a loss” on certain GAAP measures and expect continued portfolio declines, underlining execution and pricing risks in legacy products. Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.